Benign Prostatic Hyperplasia Treatment Market

Table of Content

1. Preface

    1.1. Report Scope and Market Segmentation

    1.2. Research Highlights

2. Assumptions and Research Methodology

    2.1. Assumptions and Acronyms Used

    2.2. Research Methodology

3. Executive Summary

    3.1. Global Market Size (US$ Mn) and Distribution, by Region, 2022 and 2032

    3.2. Global Treatment Market: Market Snapshot

4. Market Overview

    4.1. Global Market: Treatment Overview

    4.2. Global Market: Key Industry Developments

    4.3. Market Dynamics

    4.4. Drivers and Restraints Snapshot Analysis

    4.5. Drivers

        4.5.1. Increasing Aging Men Population All Over the World

        4.5.2. Expanding Patient Pool Due to Other Risk Factors

    4.6. Restraints

        4.6.1. Insufficient Healthcare Facilities and Unawareness of BPH Condition

        4.6.2. Patent Expiration of Benign Prostatic Hyperplasia Drugs

    4.7. Opportunities

    4.8. Global Market Revenue Projections (US$ Mn), 2022-2032

5. Key Insights

    5.1. Clinical Trial Pipeline Analysis

    5.2. U.S. Prevalence of Benign Prostatic Hyperplasia

    5.3. Re-imbursement Scenario

    5.4. Key Merger and Acquisitions

    5.5. Number of Surgeries (Unit Procedures) Performed (2019)

    5.6. Competitive Market Share Analysis By Company (2019)

    5.7. Average Cost of Benign Prostatic Hyperplasia (BPH) Treatment

    5.8. Product/Brand Analysis - 2018

        5.8.1. Urolift

        5.8.2. Rezum

6. Global Market Analysis, by Treatment

    6.1. Introduction

    6.2. Global Market Size and Forecast, by Treatment

        6.2.1. Drug Class

            6.2.1.1. Alpha-Blockers

            6.2.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)

            6.2.1.3. Phosphodiesterase-5 Enzyme Inhibitor

            6.2.1.4. Others

        6.2.2. Minimally Invasive Surgeries

            6.2.2.1. Transurethral resection of the prostate (TURP)

            6.2.2.2. Transurethral incision of the prostate (TUIP)

            6.2.2.3. Robotic Surgeries

            6.2.2.4. Transurethral microwave thermotherapy (TUMT)

            6.2.2.5. Prostatic Urethral lift

            6.2.2.6. Others

        6.2.3. Laser Therapy

        6.2.4. Others

    6.3. Global Market Analysis, by Treatment

    6.4. Global Market Attractiveness Analysis, by Treatment

7. Global Market Analysis, by End-user

    7.1. Introduction

    7.2. Global Market Size and Forecast, by End-user

        7.2.1. Hospitals

        7.2.2. Ambulatory Surgical Centers

        7.2.3. Specialty Clinics

        7.2.4. Others

    7.3. Global Market Analysis, by End-user

    7.4. Global Market Attractiveness Analysis, by End-user

8. Global Market Analysis, by Region

    8.1. Global Market Size and Forecast, by Region, 2022-2032

        8.1.1. North America

        8.1.2. Europe

        8.1.3. Asia Pacific

        8.1.4. Latin America

        8.1.5. Middle East & Africa

    8.2. Global Market Analysis, by Region

    8.3. Global Market Attractiveness Analysis, by Region

9. North America Market Analysis

    9.1. North America Market

    9.2. North America Market Overview

    9.3. North America Market Size and Forecast, by Treatment

        9.3.1. Drug Class

            9.3.1.1. Alpha-Blockers

            9.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)

            9.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor

            9.3.1.4. Others

        9.3.2. Minimally Invasive Surgeries

            9.3.2.1. Transurethral resection of the prostate (TURP)

            9.3.2.2. Transurethral incision of the prostate (TUIP)

            9.3.2.3. Robotic Surgeries

            9.3.2.4. Transurethral microwave thermotherapy (TUMT)

            9.3.2.5. Prostatic Urethral lift

            9.3.2.6. Others

        9.3.3. Laser Therapy

        9.3.4. Others

    9.4. North America Market Size and Forecast, by End-user

        9.4.1. Hospitals

        9.4.2. Ambulatory Surgical Centers

        9.4.3. Specialty Clinics

        9.4.4. Others

    9.5. North America Market Forecast, by Country

        9.5.1. U.S.

        9.5.2. Canada

    9.6. North America Market Attractiveness Analysis

        9.6.1. By Treatment

        9.6.2. By End-user

        9.6.3. By Country

10. Europe Market Analysis

    10.1. Europe Market

    10.2. Europe Market Overview

    10.3. Europe Market Size and Forecast, by Treatment

        10.3.1. Drug Class

            10.3.1.1. Alpha-Blockers

            10.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)

            10.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor

            10.3.1.4. Others

        10.3.2. Minimally Invasive Surgeries

            10.3.2.1. Transurethral resection of the prostate (TURP)

            10.3.2.2. Transurethral incision of the prostate (TUIP)

            10.3.2.3. Robotic Surgeries

            10.3.2.4. Transurethral microwave thermotherapy (TUMT)

            10.3.2.5. Prostatic Urethral lift

            10.3.2.6. Others

        10.3.3. Laser Therapy

        10.3.4. Others

    10.4. Europe Market Size and Forecast, by End-user

        10.4.1. Hospitals

        10.4.2. Ambulatory Surgical Centers

        10.4.3. Specialty Clinics

        10.4.4. Others

    10.5. Europe Market Forecast, by Country/Sub-region

        10.5.1. U.K.

        10.5.2. France

        10.5.3. Germany

        10.5.4. Spain

        10.5.5. Italy

        10.5.6. Rest of Europe

    10.6. Europe Market Attractiveness Analysis

        10.6.1. By Treatment

        10.6.2. By End-user

        10.6.3. By Country/Sub-region

11. Asia Pacific Market Analysis

    11.1. Asia Pacific Market Key Findings

    11.2. Asia Pacific Market Overview

    11.3. Asia Pacific Market Size and Forecast, by Treatment

        11.3.1. Drug Class

            11.3.1.1. Alpha-Blockers

            11.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)

            11.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor

            11.3.1.4. Others

        11.3.2. Minimally Invasive Surgeries

            11.3.2.1. Transurethral resection of the prostate (TURP)

            11.3.2.2. Transurethral incision of the prostate (TUIP)

            11.3.2.3. Robotic Surgeries

            11.3.2.4. Transurethral microwave thermotherapy (TUMT)

            11.3.2.5. Prostatic Urethral lift

            11.3.2.6. Others

        11.3.3. Laser Therapy

        11.3.4. Others

    11.4. Asia Pacific Market Size and Forecast, by End-user

        11.4.1. Hospitals

        11.4.2. Ambulatory Surgical Centers

        11.4.3. Specialty Clinics

        11.4.4. Others

    11.5. Asia Pacific Market Forecast, by Country/Sub-region

        11.5.1. China

        11.5.2. India

        11.5.3. Japan

        11.5.4. Australia & New Zealand

        11.5.5. Rest of Asia Pacific

    11.6. Asia Pacific Market Attractiveness Analysis

        11.6.1. By Treatment

        11.6.2. By End-user

        11.6.3. By Country/Sub-region

12. Latin America Market Analysis

    12.1. Latin America Market Key Findings

    12.2. Latin America Market Overview

    12.3. Latin America Market Size and Forecast, by Treatment

        12.3.1. Drug Class

            12.3.1.1. Alpha-Blockers

            12.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)

            12.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor

            12.3.1.4. Others

        12.3.2. Minimally Invasive Surgeries

            12.3.2.1. Transurethral resection of the prostate (TURP)

            12.3.2.2. Transurethral incision of the prostate (TUIP)

            12.3.2.3. Robotic Surgeries

            12.3.2.4. Transurethral microwave thermotherapy (TUMT)

            12.3.2.5. Prostatic Urethral lift

            12.3.2.6. Others

        12.3.3. Laser Therapy

        12.3.4. Others

    12.4. Latin America Market Size and Forecast, by End-user

        12.4.1. Hospitals

        12.4.2. Ambulatory Surgical Centers

        12.4.3. Specialty Clinics

        12.4.4. Others

    12.5. Latin America Market Forecast, by Country/Sub-region

        12.5.1. Brazil

        12.5.2. Mexico

        12.5.3. Rest of Latin America

    12.6. Latin America Market Attractiveness Analysis

        12.6.1. By Treatment

        12.6.2. By End-user

        12.6.3. By Country/Sub-region

13. Middle East & Africa Market Analysis

    13.1. Middle East & Africa Market

    13.2. Market Overview

    13.3. Middle East & Africa Market Size and Forecast, by Treatment

        13.3.1. Drug Class

            13.3.1.1. Alpha-Blockers

            13.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)

            13.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor

            13.3.1.4. Others

        13.3.2. Minimally Invasive Surgeries

            13.3.2.1. Transurethral resection of the prostate (TURP)

            13.3.2.2. Transurethral incision of the prostate (TUIP)

            13.3.2.3. Robotic Surgeries

            13.3.2.4. Transurethral microwave thermotherapy (TUMT)

            13.3.2.5. Prostatic Urethral lift

            13.3.2.6. Others

        13.3.3. Laser Therapy

        13.3.4. Others

    13.4. Middle East & Africa Market Size and Forecast, by End-user

        13.4.1. Hospitals

        13.4.2. Ambulatory Surgical Centers

        13.4.3. Specialty Clinics

        13.4.4. Others

    13.5. Middle East & Africa Market Forecast, by Country/Sub-region

        13.5.1. GCC Countries

        13.5.2. South Africa

        13.5.3. Rest of Middle East & Africa

    13.6. Middle East & Africa Market Attractiveness Analysis

        13.6.1. By Treatment

        13.6.2. By End-user

        13.6.3. By Country/Sub-region

14. Competition Landscape (Pharmaceutical Companies)

    14.1. Company Profiles

        14.1.1. Abbott

            14.1.1.1. Overview (HQ, Employee Strength, Business Segments)

            14.1.1.2. Financials

            14.1.1.3. Recent Developments

            14.1.1.4. Strategy

        14.1.2. Allergan Plc

            14.1.2.1. Overview (HQ, Employee Strength, Business Segments)

            14.1.2.2. Financials

            14.1.2.3. Recent Developments

            14.1.2.4. Strategy

        14.1.3. Astellas Pharma, Inc.

            14.1.3.1. Overview (HQ, Employee Strength, Business Segments)

            14.1.3.2. Financials

            14.1.3.3. Recent Developments

            14.1.3.4. Strategy

        14.1.4. Asahi Kasei Corporation

            14.1.4.1. Overview (HQ, Employee Strength, Business Segments)

            14.1.4.2. Financials

            14.1.4.3. Recent Developments

            14.1.4.4. Strategy

        14.1.5. Boehringer Ingelheim GmbH

            14.1.5.1. Overview (HQ, Employee Strength, Business Segments)

            14.1.5.2. Financials

            14.1.5.3. Recent Developments

            14.1.5.4. Strategy

        14.1.6. GlaxoSmithKline Plc.

            14.1.6.1. Overview (HQ, Employee Strength, Business Segments)

            14.1.6.2. Financials

            14.1.6.3. Recent Developments

            14.1.6.4. Strategy

        14.1.7. Pfizer, Inc.

            14.1.7.1. Overview (HQ, Employee Strength, Business Segments)

            14.1.7.2. Financials

            14.1.7.3. Recent Developments

            14.1.7.4. Strategy

        14.1.8. Sanofi SA

            14.1.8.1. Overview (HQ, Employee Strength, Business Segments)

            14.1.8.2. Financials

            14.1.8.3. Recent Developments

            14.1.8.4. Strategy

        14.1.9. Teva Pharmaceutical Industries Ltd.

            14.1.9.1. Overview (HQ, Employee Strength, Business Segments)

            14.1.9.2. Financials

            14.1.9.3. Recent Developments

            14.1.9.4. Strategy

        14.1.10. Merck & Co., Inc.

            14.1.10.1. Overview (HQ, Employee Strength, Business Segments)

            14.1.10.2. Financials

            14.1.10.3. Recent Developments

            14.1.10.4. Strategy

15. Competition Landscape (Medical Devices/Service Provider Organizations)

    15.1. Company Profiles

        15.1.1. Boston Scientific Corporation

            15.1.1.1. Overview (HQ, Employee Strength, Business Segments)

            15.1.1.2. Financials

            15.1.1.3. Recent Developments

            15.1.1.4. Strategy

        15.1.2. Teleflex Incorporated

            15.1.2.1. Overview (HQ, Employee Strength, Business Segments)

            15.1.2.2. Financials

            15.1.2.3. Recent Developments

            15.1.2.4. Strategy

        15.1.3. Endo International Plc.

            15.1.3.1. Overview (HQ, Employee Strength, Business Segments)

            15.1.3.2. Financials

            15.1.3.3. Recent Developments

            15.1.3.4. Strategy

        15.1.4. Urologix, LLC

            15.1.4.1. Overview (HQ, Employee Strength, Business Segments)

            15.1.4.2. Financials

            15.1.4.3. Recent Developments

            15.1.4.4. Strategy

        15.1.5. LISA Laser

            15.1.5.1. Overview (HQ, Employee Strength, Business Segments)

            15.1.5.2. Financials

            15.1.5.3. Recent Developments

            15.1.5.4. Strategy

        15.1.6. Olympus

            15.1.6.1. Overview (HQ, Employee Strength, Business Segments)

            15.1.6.2. Financials

            15.1.6.3. Recent Developments

            15.1.6.4. Strategy

List Of Table

TABLE 01: Prostate Cancer Therapeutics: Pipeline Analysis – Phase III (1/2)

TABLE 02: Prostate Cancer Therapeutics: Pipeline Analysis – Phase III (2/2)

TABLE 03: Prostate Cancer Therapeutics: Pipeline Analysis – Phase II (1/2)

TABLE 04: Prostate Cancer Therapeutics: Pipeline Analysis – Phase II (2/2)

TABLE 05: Prostate Cancer Therapeutics: Pipeline Analysis – Phase I

TABLE 06: 2015 Patient Population Break Down

TABLE 07: Number of Surgeries (Unit Procedures) Performed in United States (2022)

TABLE 08: Summary of Current BPH Treatments in U.S.

TABLE 09: Global Market Size (US$ Mn) Forecast, by Treatment, 2022-2032

TABLE 10: Global Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032

TABLE 11: Global Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2022-2032

TABLE 12: Global Market Size (US$ Mn) Forecast, by End-user, 2022-2032

TABLE 13: Global Market Value (US$ Mn) Forecast, by Region, 2022-2032

TABLE 14: North America Market Value (US$ Mn) Forecast, by Country, 2022-2032

TABLE 15: Global Market Size (US$ Mn) Forecast, by Treatment, 2022-2032

TABLE 16: Global Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032

TABLE 17: Global Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2022-2032

TABLE 18: North America Market Value (US$ Mn) Forecast, by End-user, 2022-2032

TABLE 19: Europe Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022-2032

TABLE 20: Europe Market Size (US$ Mn) Forecast, by Treatment, 2022-2032

TABLE 21: Europe Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032

TABLE 22: Europe Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2022-2032

TABLE 23: Europe Market Value (US$ Mn) Forecast, by End-user, 2022-2032

TABLE 24: Asia Pacific Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022-2032

TABLE 25: Asia Pacific Market Size (US$ Mn) Forecast, by Treatment, 2022-2032

TABLE 26: Asia Pacific Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032

TABLE 27: Asia Pacific Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2022-2032

TABLE 28: Asia Pacific Market Value (US$ Mn) Forecast, by End-user, 2022-2032

TABLE 29: Latin America Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022-2032

TABLE 30: Latin America Market Size (US$ Mn) Forecast, by Treatment, 2022-2032

TABLE 31: Latin America Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032

TABLE 32: Latin America Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2022-2032

TABLE 33: Latin America Market Value (US$ Mn) Forecast, by End-user, 2022-2032

TABLE 34: Middle East & Africa Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022-2032

TABLE 35: Middle East & Africa Market Size (US$ Mn) Forecast, by Treatment, 2022-2032

TABLE 36: Middle East & Africa Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032

TABLE 37: Middle East & Africa Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2022-2032

TABLE 38: Middle East & Africa Market Value (US$ Mn) Forecast, by End-user, 2022-2032

List Of Figures

FIG. 01: Global Market Size (US$ Mn) Forecast, 2022-2032

FIG. 02: Global Market Value Share, by Treatment, 2021

FIG. 03: Global Market Value Share, by Drug Class, 2021

FIG. 04: Global Market Value Share, by End-user, 2021

FIG. 05: Global Market Value Share, by Minimally Invasive Surgery, 2021

FIG. 06: Global Market Value Share Analysis, by Treatment, 2022 & 2032

FIG. 07: Global Market Revenue, by Drug Class, 2022-2032

FIG. 08: Global Market Revenue, by Minimally Invasive Surgeries, 2022-2032

FIG. 09: Global Market Revenue, by Laser Therapy, 2022-2032

FIG. 10: Global Market Revenue, by Others, 2022-2032

FIG. 11: Global Market Attractiveness Analysis, by Treatment, 2022-2032

FIG. 12: Global Market Value Share Analysis, by End-user, 2022 & 2032

FIG. 13: Global Market Revenue, by Hospitals, 2022-2032

FIG. 14: Global Market Revenue, by Ambulatory Surgical Centers, 2022-2032

FIG. 15: Global Market Revenue, by Specialty Clinics, 2022-2032

FIG. 16: Global Market Revenue, by Others, 2022-2032

FIG. 17: Global Market Attractiveness Analysis, by End-user, 2022-2032

FIG. 18: Global Market Value Share (%), by Region, 2018 and 2026

FIG. 19: Global Market Attractiveness, by Region, 2022-2032

FIG. 20: North America Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2022-2032

FIG. 21: North America Market Value Share, by Country, 2022 & 2032

FIG. 22: North America Market Attractiveness, by Country, 2022-2032

FIG. 23: North America Market Value Share Analysis, by Product, 2022 & 2032

FIG. 24: North America Market Attractiveness, by Product, 2022-2032

FIG. 25: North America Market Value Share Analysis, by End-user, 2022 & 2032

FIG. 26: North America Market Attractiveness, by End-user, 2022-2032

FIG. 27: Europe Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2022-2032

FIG. 28: Europe Market Value Share, by Country/Sub-region, 2022 & 2032

FIG. 29: Europe Market Attractiveness, by Country/Sub-region, 2022-2032

FIG. 30: Europe Market Value Share Analysis, by Product, 2022 & 2032

FIG. 31: Europe Market Attractiveness, by Product, 2022-2032

FIG. 32: Europe Market Value Share Analysis, by End-user, 2022 & 2032

FIG. 33: Europe Market Attractiveness, by End-user, 2022-2032

FIG. 34: Asia Pacific Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2022-2032

FIG. 35: Asia Pacific Market Value Share, by Country/Sub-region, 2022 & 2032

FIG. 36: Asia Pacific Market Attractiveness, by Country/Sub-region, 2022-2032

FIG. 37: Asia Pacific Market Value Share Analysis, by Product, 2022 & 2032

FIG. 38: Asia Pacific Market Attractiveness, by Product, 2022-2032

FIG. 39: Asia Pacific Market Value Share Analysis, by End-user, 2022 & 2032

FIG. 40: Asia Pacific Market Attractiveness, by End-user, 2022-2032

FIG. 41: Latin America Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2022-2032

FIG. 42: Latin America Market Value Share, by Country/Sub-region, 2022 & 2032

FIG. 43: Latin America Market Attractiveness, by Country/Sub-region, 2022-2032

FIG. 44: Latin America Market Value Share Analysis, by Product, 2022 & 2032

FIG. 45: Latin America Market Attractiveness, by Product, 2022-2032

FIG. 46: Latin America Market Value Share Analysis, by End-user, 2022 & 2032

FIG. 47: Latin America Market Attractiveness, by End-user, 2022-2032

FIG. 48: Middle East & Africa Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2022-2032

FIG. 49: Middle East & Africa Market Value Share, by Country/Sub-region, 2022 & 2032

FIG. 50: Middle East & Africa Market Attractiveness, by Country/Sub-region, 2022-2032

FIG. 51: Middle East & Africa Market Value Share Analysis, by Product, 2022 & 2032

FIG. 52: Middle East & Africa Market Attractiveness, by Product, 2022-2032

FIG. 53: Middle East & Africa Market Value Share Analysis, by End-user, 2022 & 2032

FIG. 54: Middle East & Africa Market Attractiveness, by End-user, 2022-2032

FIG. 55: Global Devices Market Share Analysis, by Company (2019)

FIG. 56: GlaxoSmithKline plc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2017-2021

FIG. 57: GlaxoSmithKline plc. R&D Expenses and Selling, General and Administration Expenses (US$ Bn) - Company Level, 2017-2021

FIG. 58: GlaxoSmithKline plc. Breakdown of Net Sales, by Region/Country (Company Level), 2018

FIG. 59: GlaxoSmithKline plc. Breakdown of Net Sales, by Business Segment (Overall Company Level), 2018

FIG. 60: Sanofi R&D Expenses (US$ Bn) and Y-o-Y Growth (%), 2017-2021

FIG. 61: Sanofi Breakdown of Net Sales (%), by Region/Country, 2018

FIG. 62: Sanofi Revenue (US$ Bn) and Y-o-Y Growth (%), 2017-2021

FIG. 63: Pfizer, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2017-2021

FIG. 64: Pfizer, Inc. Breakdown of Net Sales, by Region/Country, 2018

FIG. 65: Pfizer, Inc. R&D Expenses (US$ Bn) and Y-o-Y Growth (%), 2017-2021

FIG. 66: Pfizer, Inc. Breakdown of Net Sales, by Business Segment (%), 2018

FIG. 67: Teva Pharmaceutical Industries Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2021

FIG. 68: Teva Pharmaceutical Industries Ltd. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017-2021

FIG. 69: Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Region, 2018

FIG. 70: Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Operating Segment, 2017

FIG. 71: Abbott Laboratories Revenue (US$ Bn) and Y-o-Y Growth (%), 2017-2021

FIG. 72: Abbott Laboratories R&D Intensity and Sales & Marketing Intensity – Company Level, 2017-2021

FIG. 73: Abbott Laboratories Breakdown of Net Sales, by Segment, 2018

FIG. 74: Abbott Breakdown of Net Sales (%), by Country/Sub-region, 2018

FIG. 75: Allergan plc Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2021

FIG. 76: Allergan plc Breakdown of Net Sales (%), by Geography, 2018

FIG. 77: Allergan plc R&D Expenses and Marketing & Sales Intensity (%) 2017-2021

FIG. 78: Allergana plc Breakdown of Net Sales (%), by Business Segment, 2018

FIG. 79: Endo Pharmaceuticals, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2021

FIG. 80: Endo Pharmaceuticals, Inc. Breakdown of Net Sales (%), by Region, 2016

FIG. 81: Endo Pharmaceuticals, Inc. total Acquisition-related and Integration Items, Expenses in 2017-2021

FIG. 82: Endo Pharmaceuticals, Inc. Breakdown of Net Sales (%), by Specialty Products, 2018

FIG. 83: Boehringer Ingelheim GmbH Revenue (US$ Bn) and Y-o-Y Growth (%), 2017-2021

FIG. 84: Boehringer Ingelheim GmbH Breakdown of Net Sales, by Region (Company Level), 2018

FIG. 85: Boehringer Ingelheim GmbH Breakdown of Net Sales, by Business and Business Segment Level, 2017

FIG. 86: Boehringer Ingelheim GmbH R&D Expenditure (US$ Mn), 2017-2021

FIG. 87: Merck & Co., Inc. Break-up of Net Sales, by Region, 2021

FIG. 88: Merck & Co., Inc. Pharmaceutical Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2021

FIG. 89: Merck & Co., Inc. R&D Intensity (%) - Company Level or Segment Level, 2017-2021

FIG. 90: Asahi Kasei Corporation Revenue (US$ Bn) and Y-o-Y Growth (%), 2017-2021

FIG. 91: Asahi Kasei Corporation R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017-2021

FIG. 92: Asahi Kasei Corporation Breakdown of Net Sales (%), by Business Segment, 2018

FIG. 93: Astellas Pharma, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2017-2021

FIG. 94: Astellas Pharma, Inc. Breakdown of Net Sales (%), by Region, 2021

FIG. 95: Astellas Pharma, Inc. R&D expenses (US$ Bn) in 2017-2021

FIG. 96: Astellas Pharma, Inc. Breakdown of Net Sales (%), by Main Products, 2021

FIG. 97: Teleflex Incorporated, Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2021

FIG. 98: Teleflex Incorporated, Breakdown of Net Sales (%), by Business Segment, 2021

FIG. 99: Teleflex Incorporated, Breakdown of Net Sales (%), by Geography, 2021

FIG. 100: Boston Scientific Corporation Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2021

FIG. 101: Boston Scientific Corporation Breakdown of Net Sales (%), by Business Segment, 2021

FIG. 102: Boston Scientific Corporation Breakdown of Net Sales (%), by Country, 2017

FIG. 103: Boston Scientific Corporation R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017-2021

FIG. 104: Olympus Corporation Revenue (US$ Bn) and Y-o-Y Growth (%), 2017-2021

FIG. 105: Olympus Corporation Breakdown of Net Sales (%), by Region, 2021

FIG. 106: Olympus Corporation Breakdown of Net Sales (%), by Medical Business Segment, 2021